Pedmark is a formulation of sodium thiosulfate meant for preventing platinum-induced ototoxicity in pediatric patients with localized, non-metastatic, solid tumors, the company said.
The FDA had refused to accept the Pedmark new drug application in November due to certain manufacturing deficiencies, according to a statement.
FENC stock price gained 4.9% in after-hours trading on Wednesday.